FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Full story
Read the full story at CNBC ↗
Continue reading this story on CNBC, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
